## **Product** Data Sheet

# VEGFR2-IN-2

Cat. No.: HY-147133 CAS No.: 737818-56-3 Molecular Formula:  $C_{15}H_{11}BrN_2O$ Molecular Weight: 315.16 Target: **VEGFR** 

Pathway: Protein Tyrosine Kinase/RTK

Storage: Powder -20°C 3 years

4°C 2 years In solvent -80°C 6 months

-20°C 1 month

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (317.30 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.1730 mL	15.8650 mL	31.7299 mL
	5 mM	0.6346 mL	3.1730 mL	6.3460 mL
	10 mM	0.3173 mL	1.5865 mL	3.1730 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.93 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.93 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	VEGFR2-IN-2 (compound 6e) is a potent and selective VEGFR2 inhibitor with an IC <sub>50</sub> of 19.32 nM. VEGFR2-IN-2 can be used for researching
IC <sub>50</sub> & Target	VEGFR2 19.32 nM (IC <sub>50</sub> )

#### **REFERENCES**

1]. Sun J, et al. Design, synthesis, biological evaluation, and molecular modeling study of 4-alkoxyquinazoline derivatives as potential VEGFR2 kinase inhibitors. Org 3iomol Chem. 2013 Nov 28;11(44):7676-86.						
	Caution: Product has r	not been fully validated for me	edical applications. For research use only.			
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.com			
	Address: 1	1 Deer Park Dr, Suite Q, Monmo	outh Junction, NJ 08852, USA			

Page 2 of 2 www.MedChemExpress.com